Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions.

Nonnative aggregation is a common degradation route for therapeutic proteins. Control of aggregate levels inherently requires control and/or prediction of aggregation rates at formulation conditions and storage temperatures of practical interest. Additionally, formulation screening often involves generation of accelerated stability data at one or more temperatures. A temperature-scanning approach for measuring nonnative aggregation rates as a function of temperature is proposed and evaluated here for a monoclonal antibody across different formulation conditions. Observed rate coefficients of aggregation (kobs ) were determined from isothermal kinetic studies for a range of pH and salt conditions at several temperatures, corresponding to shelf lives spanning multiple orders of magnitude. Isothermal kobs values were efficiently and quantitatively predicted by the temperature-scanning monomer loss (TSML) approach at accelerated conditions (half lives of the order 10(-1) -10(2) h). At lower temperatures, non-Arrhenius behavior was apparent in some cases, and was semi-quantitatively described by nonlinear van't Hoff contributions to monomer unfolding free energies. Overall, the results demonstrate a novel strategy to quantitatively determine aggregation rates at time scales of industrial interest, based on kobs values from TSML, which are sample- and time-sparing as compared with traditional isothermal approaches, and illustrate challenges for shelf-life prediction with non-Arrhenius kinetics.

[1]  A. Oliva,et al.  New Trends in Analysis of Biopharmaceutical Products , 2007 .

[2]  D. Milardi,et al.  An alternative approach in the structure-based predictions of the thermodynamics of protein unfolding. , 1997, Biophysical chemistry.

[3]  E. Landau,et al.  The Hofmeister series: salt and solvent effects on interfacial phenomena , 1997, Quarterly Reviews of Biophysics.

[4]  P. Privalov Stability of proteins. Proteins which do not present a single cooperative system. , 1982, Advances in protein chemistry.

[5]  A. Fink Protein aggregation: folding aggregates, inclusion bodies and amyloid. , 1998, Folding & design.

[6]  Christopher J Roberts,et al.  Non‐native protein aggregation kinetics , 2007, Biotechnology and bioengineering.

[7]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[8]  William F Weiss,et al.  Principles, approaches, and challenges for predicting protein aggregation rates and shelf life. , 2009, Journal of pharmaceutical sciences.

[9]  C. Winsor,et al.  The Gompertz Curve as a Growth Curve. , 1932, Proceedings of the National Academy of Sciences of the United States of America.

[10]  C. Roberts,et al.  Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms. , 2011, Journal of pharmaceutical sciences.

[11]  C. Roberts,et al.  Non-native aggregation of alpha-chymotrypsinogen occurs through nucleation and growth with competing nucleus sizes and negative activation energies. , 2007, Biochemistry.

[12]  M. Verheul,et al.  Kinetics of Heat-Induced Aggregation of β-Lactoglobulin , 1998 .

[13]  O. Velev,et al.  Protein interactions in solution characterized by light and neutron scattering: comparison of lysozyme and chymotrypsinogen. , 1998, Biophysical journal.

[14]  V. Hilser,et al.  The heat capacity of proteins , 1995, Proteins.

[15]  J L Cleland,et al.  The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. , 1993, Critical reviews in therapeutic drug carrier systems.

[16]  T. Arakawa,et al.  Effect of additives on protein aggregation. , 2009, Current pharmaceutical biotechnology.

[17]  Christopher J Roberts,et al.  Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. , 2011, Journal of pharmaceutical sciences.

[18]  W. J. Becktel,et al.  Protein stability curves , 1987, Biopolymers.

[19]  Michele Vendruscolo,et al.  Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. , 2004, Journal of molecular biology.

[20]  Christopher J Roberts,et al.  A Lumry-Eyring nucleated polymerization model of protein aggregation kinetics: 1. Aggregation with pre-equilibrated unfolding. , 2007, The journal of physical chemistry. B.

[21]  P. Privalov Stability of proteins: small globular proteins. , 1979, Advances in protein chemistry.

[22]  Christopher J Roberts,et al.  Irreversible aggregation of recombinant bovine granulocyte-colony stimulating factor (bG-CSF) and implications for predicting protein shelf life. , 2003, Journal of pharmaceutical sciences.

[23]  D. Kalonia,et al.  Nature and consequences of protein-protein interactions in high protein concentration solutions. , 2008, International journal of pharmaceutics.

[24]  S. Yoshioka,et al.  Is Stability Prediction Possible for Protein Drugs? Denaturation Kinetics of β- Galactosidase in Solution , 1994, Pharmaceutical Research.

[25]  G. Barone,et al.  Prediction of the heat capacity change on thermal denaturation of globular proteins , 1998 .

[26]  J. Ramsey,et al.  Immunoglobulin dynamics, conformational fluctuations, and nonlinear elasticity and their effects on stability. , 2008, The journal of physical chemistry. B.

[27]  William F. Weiss,et al.  Nucleation, growth, and activation energies for seeded and unseeded aggregation of alpha-chymotrypsinogen A. , 2008, Biochemistry.

[28]  C. Roberts,et al.  Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization. , 2009, The journal of physical chemistry. B.

[29]  John F. Carpenter,et al.  Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.

[30]  Christopher J Roberts,et al.  Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. , 2010, Journal of pharmaceutical sciences.

[31]  Wei Wang,et al.  Protein aggregation and its inhibition in biopharmaceutics. , 2005, International journal of pharmaceutics.

[32]  Babatunde A. Ogunnaike,et al.  Multi-variate approach to global protein aggregation behavior and kinetics: effects of pH, NaCl, and temperature for alpha-chymotrypsinogen A. , 2010, Journal of pharmaceutical sciences.

[33]  T. Dillon,et al.  Conformational implications of an inversed pH-dependent antibody aggregation. , 2009, Journal of pharmaceutical sciences.